Back to Search Start Over

Remsima (a Tumor Necrosis Factor (TNF) -α Inhibitor) induced hemolysis in a patient with Crohn's disease - Case report

Authors :
N.Y. Zakary
Hind Hamid
Rehab Y Al-Ansari
Arwa Al. Khuraim
Leena Abdalla
Source :
Annals of Medicine and Surgery
Publication Year :
2021
Publisher :
Ovid Technologies (Wolters Kluwer Health), 2021.

Abstract

Introduction Crohn's disease (CD) is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. Infliximab is a treatment modality for fistulated Crohn's disease. Infliximab induced hemolysis is rare and very few cases reported before in Ulcerative colitis (UC) but not in Crohn's disease. Case presentation We are reporting a 63 years old gentleman who was diagnosed as Crohn's disease and started on Tumor necrosis factor Inhibitor (TNF) -α i.e. (infliximab - Remsima) infusion. The course was complicated by Coomb's negative hemolytic anemia which is suggestive of non-immune drug induced hemolysis. Our patient was treated with steroid and conservative measures. Upon following up, his hemoglobin level as well as all hemolytic markers showed dramatic improvement. Adalimumab was used to treat this patient as an alternative choice without relapse of hemolysis. Clinical discussion Drug induced Hemolysis is not a well-known complication post receiving Tumor necrosis factor Inhibitor (TNF) -α infusion in patients with Crohn's disease. Coombs negative hemolysis keeps in favor of non-immune drug induced rather than other differentials in our case scenario. Conclusion Although cross-reactivity is expected between one biological agent to another, in our case the use of Adalimumab as alternative choice post Tumor necrosis factor Inhibitor (TNF) -α (Remsima infliximab) induced hemolysis did not cause hemolysis or any type of reaction.<br />Highlights • Crohn's disease is one of the Inflammatory bowel diseases (IBD) that can affect any part of gastrointestinal tract as well as extraintestinal organs. • Tumor necrosis factor Inhibitor (TNF) -α i.e. (infliximab - Remsima) is a treatment modality for fistulated Crohn's disease. • Drug induced Hemolysis is one of the complications that is not well-known post receiving Tumor necrosis factor Inhibitor (TNF) -α (Remsima) infusion.

Details

ISSN :
20490801
Volume :
69
Database :
OpenAIRE
Journal :
Annals of Medicine & Surgery
Accession number :
edsair.doi.dedup.....4b3d8c849f7fc9160b6da5024a931623
Full Text :
https://doi.org/10.1016/j.amsu.2021.102768